Related references
Note: Only part of the references are listed.Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β-lactamases and carbapenemases)
Joseph P. Lynch et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Tissue pharmacokinetics of ertapenem at steady-state in diabetic patients with leg infections
Robert Sauermann et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study
George G. Zhanel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11
Andrew J. Denisuik et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Risk factors and treatment outcome of ertapenem non-susceptible enterobacteriaceae bacteraemia
Kalisvar Marimuthu et al.
JOURNAL OF INFECTION (2013)
Clinical Outcomes with Ertapenem as a First-Line Treatment Option of Infections Caused by Extended-Spectrum β-Lactamase Producing Gram-Negative Bacteria
Jeffrey J. Fong et al.
ANNALS OF PHARMACOTHERAPY (2012)
Carbapenem Therapy for Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli or Klebsiella pneumoniae: Implications of Ertapenem Susceptibility
Nan-Yao Lee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Efficacy of Ertapenem for Treatment of Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
Vicki L. Collins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010
Daryl J. Hoban et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2012)
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum -lactamases: a systematic review and meta-analysis
Konstantinos Z. Vardakas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Prolonged subcutaneous high dose (1 g bid) of Ertapenem as salvage therapy in patients with difficult-to-treat bone and joint infection
Tristan Ferry et al.
JOURNAL OF INFECTION (2012)
Ertapenem administered intravenously or subcutaneously for urinary tract infections caused by ESBL producing enterobacteriacea
E. Forestier et al.
MEDECINE ET MALADIES INFECTIEUSES (2012)
Risk Factors, Molecular Epidemiology and Outcomes of Ertapenem-Resistant, Carbapenem-Susceptible Enterobacteriaceae: A Case-Case-Control Study
Jocelyn Teo et al.
PLOS ONE (2012)
The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria
F. G. De Rosa et al.
INFECTION (2011)
Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum β-lactamase-producing Escherichia coli using an in vitro model
George G. Zhanel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Share Paper
